Acquisition provides growth opportunities and increases synergies within the ProScan Family of Companies
ProScan Imaging, one an international radiology services group, has increased its majority ownership of WorldCare Clinical (WCC) LLC to 100 percent, aiming to position the organization for growth and increased synergies in technology, service offerings, expertise, and accredited educational programs to benefit their biopharmaceutical and device manufacturer customers.
“The acquisition allows us to more closely align WCC’s exceptional trial management and assessment accuracy and consistency testing methodology with ProScan’s world-wide medical image file exchange platform and its international teleradiology assets,” stated Michael O’Brien, President and COO of the ProScan Family of Companies. “The enhanced service delivery model will allow WCC’s customers to lower their trial costs, while flexibly accessing the most appropriate independent expert assessment team.”
“Our access to large groups of sub-specialty trained, practicing radiologists and clinicians at ProScan and Harvard teaching hospitals coupled with our rapid turnaround global teleradiology and telemedicine endpoint assessment committees (EACs), all uniquely position us to take advantage of the ever changing and more rigorous clinical trial requirements,” stated Dr. Richard Walovitch, President of WCC. “As the number of stakeholders involved in product life cycle management increases, WCC can provide continuity and efficiency of service, effective efficacy and safety evaluation, reporting, and continuing medical education, informing these stakeholders on the best path for their product from early clinical trial activity through commercialization.”
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.